Fondation Defitech, Morges
Address
Fondation DefitechGrand-Rue 57
c/o Maurice Rapit, Conseil Fiduciaire et Fiscal SA
1110 Morges
Complete data
Latest commercial register entry
Map & Directions
Review
Commercial register ID for Fondation Defitech:
CH-550.1.024.308-5
Unique enterprise identification number (UID) for Fondation Defitech:
CHE-109.807.245
About the company Fondation Defitech
Fondation Defitech, based in Morges, is a company in Switzerland. Fondation Defitech is active according to the commercial register. Fondation Defitech was registered in the Swiss Commercial Register on April 18, 2001. Its UID is CHE-109.807.245. In the database of the IGE (Swiss Federal Institute for Intellectual Property) there are currently trademarks or applications for the company Fondation Defitech.
A total of 13 official publications concerning Fondation Defitech have been recorded on HELP.CH in the Swiss Official Gazette of Commerce (SOGC) database, which contains publications from January 2007 onwards. You can see the latest publication by company Fondation Defitech from April 24, 2025 on this link.
Purpose of the company Fondation Defitech
The purpose of the company Fondation Defitech in Morges is as follows. to contribute, in Switzerland and abroad, to the research and development of any product and any technology intended mainly to help people suffering from a physical, psychological or mental handicap. The foundation finances by donations, loans, equity investments or by any other means, companies, associations or organizations, private or public, devoting their activity to research, development, production or marketing of new technologies that may be of use to persons with disabilities.
Translated by google.comThe company Fondation Defitech in Morges is listed on Yellowpages.swiss. Latitude and longitude coordinates for Fondation Defitech are: 46.509161 and 6.4986491. The Swiss enterprise identification number (UID) of Fondation Defitech is CHE-109.807.245.
Primary Data Source: Swiss Commercial Register (SOGC / FSO)
Location of Fondation Defitech in Morges
Map display based on the published company address.
Other companies registered at the same address as Fondation Defitech (Grand-Rue 57, 1110 Morges) include: Maurice Rapit, Conseil Fiduciaire et Fiscal SA | MHR Révision S.A. | GOLAZ .
Press Releases from Fondation Defitech
Frequently Asked Questions about Fondation Defitech in Morges
We have compiled the most important questions and answers about Fondation Defitech in Morges.
What is the registered address of Fondation Defitech?
The registered business address of Fondation Defitech is Grand-Rue 57, c/o Maurice Rapit, Conseil Fiduciaire et Fiscal SA, 1110 Morges.
When was Fondation Defitech founded?
The Swiss Commercial Register entry for Fondation Defitech is dated April 18, 2001. The company may have been established before this date.
Info about Morges
The enterprise Fondation Defitech is registered in the city of Morges. Morges is a municipality in the canton of Vaud. Vaud is a canton in Romandy, the francophone part of Switzerland, and is part of the Geneva-Lausanne metropolitan region. The capital and largest city is Lausanne. The canton of Vaud is one of 26 cantons in the Swiss Confederation.
Morges is a municipality in the canton of Vaud, in the country of Switzerland, on the continent of Europe. Latitude and longitude coordinates for Morges are: 46.5088127 and 6.4961301. The local date and time in Morges is October 13, 2026, 1:55 AM.
The information on this entry in the commercial register of the legal entity Fondation Defitech is provided without guarantee and has no legal effect. Only the certified extracts from the commercial register and the publication texts in the Swiss Official Gazette of Commerce (SOGC) are binding.
Search Directory
Centiel obtains UL certification and receives USD 51 million U.S. purchase order; U.S. deliveries expected in 2027 Centiel SA, 2026-10-12
lastminute.com announces appointment of Ludovic Boisseau as Chief Financial Officer lastminute.com Group, 2026-10-12
Aprocitentan efficacy data reinforce endothelin pathway blockade as a distinct therapeutic approach across the cardiomet Idorsia Pharmaceuticals Ltd, 2026-10-12
